Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-biomarins-roctavian-valoctocogene-roxaparvovec-rvox-the-first-and-only-gene-therapy-for-adults-with-severe-hemophilia-a-301867403.html
0
0
U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A - PR Newswire
6/29/23 at 6:34pm
Organization
PRNewswire
Authors
Details
45 words
Summarize
Business & Industrial
Health
BioMarin
FDA
Nasdaq
ROCTAVIANTM
valoctocogene roxaparvovec-rvox
PRNewswire
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...